Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275444 · ClinicalTrials.gov registry record · Phase 2
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
NCT00275444 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 216 participants.
The verdict
NCT00275444, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
Study Summary
A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and laboratory profile measures would be selected for further clinical study.
Interventions
- DRUG Tipranavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2002-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275444
The ClinicalTrials.gov registry entry for NCT00275444 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tipranavir is the first listed.
NCT00275444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275444 about?
NCT00275444 is a clinical study titled "3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study". A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, an...
What is the current status of trial NCT00275444?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2002-03-29.
What interventions are being tested in trial NCT00275444?
The interventions under investigation include: Tipranavir (DRUG).
Who is sponsoring clinical trial NCT00275444?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.